US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Aptevo Therapeutics

0.9981

-0.1619-13.96%

Volume:272.03K

Turnover:280.39K

Market Cap:1.46M

PE:-0.01

High:1.18

Open:1.11

Low:0.9423

Close:1.16

Loading ...

Overview Company News Filings

Aptevo Therapeutics Says Two Additional Patients In Early-Stage Leukemia Trial Achieve Remission Within 30 Days of Treatment

Sector Update: Health Care Stocks Mixed in Afternoon Trading

MT Newswires Live

Aptevo Therapeutics Reports 2 More Remissions in AML Trial

MT Newswires Live

RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment

ACCESS Newswire

Aptevo to Participate in March Conferences

ACCESS Newswire

Aptevo Therapeutics files $100M mixed securities shelf

Aptevo Therapeutics 22024 EPS $(87.38), Cash Position $8.7M

Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update

ACCESS Newswire

Aptevo's Peter Pavlik, PhD, Chairing Session on "Bi and Multispecific Biologics" at Cambridge Healthcare Institute's Pep Talk 2025

Aptevo Therapeutics (APVO) Receives a Buy from Roth MKM

Aptevo Therapeutics Shares Slump After Warrant Exercised at a Discount

MT Newswires Live

Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds

Aptevo Therapeutics Shares Rally After Trial Results Show Complete Remission by Acute Myeloid Leukemia Patients

MT Newswires Live

Aptevo Therapeutics trading halted, volatility trading pause

Aptevo Therapeutics announces results from cohort 1 in frontline AML trial

100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial

BRIEF-Aptevo Therapeutics Announces Details On Preclinical Bispecific Antibody APVO442

Aptevo Therapeutics Inc - Announces Details on Preclinical Bispecific Antibody Apvo442

THOMSON REUTERS

Aptevo Therapeutics announces additional details about APVO442

Bispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/APVO/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"APVO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"APVO\",,,,,undefined,":{"symbol":"APVO","market":"US","secType":"STK","nameCN":"Aptevo Therapeutics","latestPrice":0.9981,"timestamp":1743537600000,"preClose":1.16,"halted":0,"volume":272028,"delay":0,"floatShares":1458281,"shares":1458445,"eps":-87.38416,"marketStatus":"Pre-Market Trading","change":-0.1619,"latestTime":"04-02 04:11:44 EDT","open":1.11,"high":1.18,"low":0.9423,"amount":280388.7261744,"amplitude":0.204914,"askPrice":1.22,"askSize":100,"bidPrice":0.96,"bidSize":300,"shortable":0,"etf":0,"ttmEps":-87.38416,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1743600600000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":0.9981,"postHourTrading":{"tag":"盘后","latestPrice":0.96,"preClose":0.9981,"latestTime":"19:59 EDT","volume":13720,"amount":13883.8742,"timestamp":1743551978160},"volumeRatio":1.6671896540492275},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"APVO\",,,,,undefined,":{"symbol":"APVO","floatShares":1458281,"roa":"-76.06%","roe":"-284.28%","lyrEps":-87.38416,"volumeRatio":1.6671896540492275,"shares":1458445,"dividePrice":0,"high":1.18,"amplitude":0.204914,"preClose":1.16,"low":0.9423,"week52Low":0.9423,"pbRate":"0.31","week52High":180.19,"institutionHeld":0,"latestPrice":0.9981,"committee":0.5,"eps":-87.38416,"divideRate":0,"volume":272028,"delay":0,"ttmEps":-87.38416,"open":1.11,"prevYearClose":4.31,"prevWeekClose":1.12,"prevMonthClose":1.16,"prevQuarterClose":1.16,"fiveDayClose":1.79,"twentyDayClose":2.95,"sixtyDayClose":4.57},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"APVO\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2521493824","title":"Aptevo Therapeutics Says Two Additional Patients In Early-Stage Leukemia Trial Achieve Remission Within 30 Days of Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2521493824","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521493824?lang=en_us&edition=fundamental","pubTime":"2025-03-21 02:26","pubTimestamp":1742495195,"startTime":"0","endTime":"0","summary":"On Thursday, Aptevo Therapeutics  announced two additional frontline Acute Myeloid Leukemia  patients have achieved remission within 30 days of treatment in the RAINIER dose optimization trial of mipletamig in combination with standard of care for patients unfit for intensive chemotherapy.9 of 10 frontline patients across two trials achieved remission when receiving the triplet combination of mipletamig + venetoclax + azacitidine .Notably, no cytokine release syndrome  has been reported in the RAINIER trial to date.Together with the addition of these interim Cohort 2 results, mipletamig has achieved a compelling overall remission rate of 90% among frontline patients, outperforming the doublet remission rate from a venetoclax + azacitidine-only study of 66%.In December 2024, Aptevo Therapeutics announced that 100% of patients achieved remission within 30 days in Cohort 1 of the RAINIER frontline acute myeloid leukemia  Phase 1b trial, including two patients who experienced complete remi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aptevo-therapeutics-says-two-additional-182635823.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4161","LU2065731478.USD","IE00B7SZL793.SGD","BK4006","IE00B66KJ199.SGD","IE00B19Z4B17.USD","IE0031619046.USD","CR","BK4139","APVO","SSI","CRS"],"gpt_icon":0},{"id":"2521646700","title":"Sector Update: Health Care Stocks Mixed in Afternoon Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2521646700","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521646700?lang=en_us&edition=fundamental","pubTime":"2025-03-21 02:02","pubTimestamp":1742493728,"startTime":"0","endTime":"0","summary":"Health care stocks were mixed Thursday afternoon, with the NYSE Health Care Index rising 0.3% and the Health Care Select Sector SPDR Fund  fractionally lower.The iShares Biotechnology ETF  fell 1.1%.In corporate news, Aspire Biopharma  shares rose 2.3% after it said Thursday its contract manufacturer Glatt Air Techniques produced the first clinical batch of pharmaceutical-grade oral mucosal form of aspirin with Aspire's formulation ahead of a bioavailability study expected to begin in April.OptiNose  shares surged 52% after the company overnight said it agreed to be acquired by Paratek Pharmaceuticals in a deal valued at up to $330 million.Aptevo Therapeutics  shares added 1.1% after it said Thursday that two additional acute myeloid leukemia patients achieved remission within 30 days of treatment in a trial evaluating mipletamig with standard therapy for patients unfit for intensive chemotherapy.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","XLV","BK4588","IBB","OPTN","BK4139","APVO","ASBP","BK4007","BK4581"],"gpt_icon":1},{"id":"2520454617","title":"Aptevo Therapeutics Reports 2 More Remissions in AML Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2520454617","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520454617?lang=en_us&edition=fundamental","pubTime":"2025-03-20 21:26","pubTimestamp":1742477176,"startTime":"0","endTime":"0","summary":"Aptevo Therapeutics  said Thursday that two additional acute myeloid leukemia patients achieved remission within 30 days of treatment in a trial evaluating mipletamig with standard therapy for patients unfit for intensive chemotherapy.The company said nine of ten frontline patients across two studies have now reached remission with the triplet combination of mipletamig, venetoclax, and azacitidine.Cohort 2 of the trial is nearly fully enrolled, with patients receiving the same dose used in an earlier expansion study, Aptevo said, adding that one patient in the latest cohort progressed and died from causes unrelated to the treatment.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["APVO","BK4139"],"gpt_icon":0},{"id":"2520452538","title":"RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2520452538","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520452538?lang=en_us&edition=fundamental","pubTime":"2025-03-20 20:35","pubTimestamp":1742474100,"startTime":"0","endTime":"0","summary":"Across two trials, 9 of 10 frontline AML patients achieved remission when treated with mipletamig in combination with the standard of care. Triplet Combination with mipletamig continues to outperform doublet combination benchmark. No Cytokine Release Syndrome  has been observed in the RAINIER trial to date. The data builds on previously reported favorable outcomes from RAINIER's Cohort 1 and the completed dose expansion trial where 100% of frontline patients achieved remission. Together with the addition of these interim Cohort 2 results, mipletamig has achieved a compelling overall remission rate of 90% among frontline patients. This outperforms the doublet remission* rate from a venetoclax + azacitidine only study, of 66%. Additionally, the frontline patient triplet therapy CR rate of 70% outperforms the CR rate from a venetoclax + azacitidine only study of 36% .Thus far, all RAINIER patients who achieved remission remain in remission.Two patients achieved remission withing 30 days o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rainier-trial-data-two-additional-123500697.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","IE00B66KJ199.SGD","LU2065731478.USD","CRS","BK4006","CR","IE00B19Z4B17.USD","IE00B7SZL793.SGD","APVO","BK4161","IE0031619046.USD"],"gpt_icon":0},{"id":"2517753152","title":"Aptevo to Participate in March Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2517753152","media":"ACCESS Newswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517753152?lang=en_us&edition=fundamental","pubTime":"2025-03-06 21:00","pubTimestamp":1741266000,"startTime":"0","endTime":"0","summary":"SEATTLE, WA / ACCESS Newswire / March 6, 2025 / Aptevo Therapeutics Inc. , a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR and ADAPTIR-FLEX platform technologies, today announced that the Company is participating in two conferences in March, as follows:. The 37th Annual Roth Conference March 16-18, 2025 in Dana Point, CA. Aptevo will participate in a fireside chat with covering analyst Jonathan Aschoff while onsite.The conference will consist of 1-on-1 / small group meetings, analyst-selected fireside chats, industry keynotes and panels with executive management attending from approximately 450 private and public companies in a variety of growth sectors. Bio-Europe Springtime Partnering Event March 17-19, 2025 in Milan, Italy.The event brings together almost 4,000 attendees, facilitates relationship building and meetings between and among companies across the biotechnology and biopharmaceutical industries.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aptevo-participate-march-conferences-130000991.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["APVO","BK4139"],"gpt_icon":0},{"id":"2511617755","title":"Aptevo Therapeutics files $100M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2511617755","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511617755?lang=en_us&edition=fundamental","pubTime":"2025-02-15 05:15","pubTimestamp":1739567713,"startTime":"0","endTime":"0","summary":"16:14 EST Aptevo Therapeutics (APVO) files $100M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-movin...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aptevo-therapeutics-files-100m-mixed-securities-shelf?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aptevo-therapeutics-files-100m-mixed-securities-shelf?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","APVO"],"gpt_icon":0},{"id":"2511660367","title":"Aptevo Therapeutics 22024 EPS $(87.38), Cash Position $8.7M","url":"https://stock-news.laohu8.com/highlight/detail?id=2511660367","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511660367?lang=en_us&edition=fundamental","pubTime":"2025-02-14 21:09","pubTimestamp":1739538584,"startTime":"0","endTime":"0","summary":"Aptevo Therapeutics 22024 EPS $(87.38), Cash Position $8.7M","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/02/43727920/aptevo-therapeutics-22024-eps-87-38-cash-position-8-7m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Aptevo Therapeutics 22024 EPS $(87.38), Cash Position $8.7M","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APVO"],"gpt_icon":0},{"id":"2511066016","title":"Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2511066016","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511066016?lang=en_us&edition=fundamental","pubTime":"2025-02-14 21:05","pubTimestamp":1739538300,"startTime":"0","endTime":"0","summary":"100% of Patients Achieved Remission Within 30 Days in Cohort 1 of the Mipletamig RAINIER Dose Optimization Trial for Frontline AML Patients, Trial Enrollment Continues. Promising Data, including a 59% Stable Disease Rate, in ALG.APV-527 Phase 1 Trial for the Treatment of Multiple Solid Tumors Makes the Case for Continued Development of First-in-Class Anti-Cancer Agent. SEATTLE, WA / ACCESS Newswire / February 14, 2025 / Aptevo Therapeutics Inc. , a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR and ADAPTIR-FLEX platform technologies, today reported financial results for the year ended December 31, 2024 and provided a business update.The Company anticipates providing multiple data readouts in 2025 and to present results at the American Society of Hematology meeting in the f","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aptevo-therapeutics-reports-2024-financial-130500794.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B19Z4B17.USD","IE00B66KJ199.SGD","IE0031619046.USD","CRS","BK4161","CR","IE00B7SZL793.SGD","BK4006","APVO","LU2065731478.USD","BK4139"],"gpt_icon":0},{"id":"2503664936","title":"Aptevo's Peter Pavlik, PhD, Chairing Session on \"Bi and Multispecific Biologics\" at Cambridge Healthcare Institute's Pep Talk 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2503664936","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503664936?lang=en_us&edition=fundamental","pubTime":"2025-01-15 21:00","pubTimestamp":1736946000,"startTime":"0","endTime":"0","summary":"Also giving an in-session talk titled \"Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR Platform,\" showcasing Aptevo's drug engineering and rational drug design expertise. SEATTLE, WA / ACCESSWIRE / January 15, 2025 / Aptevo Therapeutics   today announced that Peter Pavlik, PhD, Senior Director of Protein Engineering, will chair a session titled \"Bi and Multispecific Biologics\" and present a talk,\"Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR Platform,\" at the Cambridge Healthcare Institute's Pep Talk conference today.Talk Title: Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR Platform . Session Chair and Talk Presenter: Peter Pavlik, PhD. Date/Time: Wednesday, January 15th from 3:15-5:20 US Pacific time.This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fac","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aptevos-peter-pavlik-phd-chairing-130000329.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4137","BK4139","HCSG","APVO"],"gpt_icon":0},{"id":"2493427075","title":"Aptevo Therapeutics (APVO) Receives a Buy from Roth MKM","url":"https://stock-news.laohu8.com/highlight/detail?id=2493427075","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493427075?lang=en_us&edition=fundamental","pubTime":"2024-12-21 02:41","pubTimestamp":1734720070,"startTime":"0","endTime":"0","summary":"In a report released today, Jonathan Aschoff from Roth MKM maintained a Buy rating on Aptevo Therapeutics (APVO – Research Report), with a price ta...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/aptevo-therapeutics-apvo-receives-a-buy-from-roth-mkm?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/aptevo-therapeutics-apvo-receives-a-buy-from-roth-mkm?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","APVO"],"gpt_icon":0},{"id":"2491330809","title":"Aptevo Therapeutics Shares Slump After Warrant Exercised at a Discount","url":"https://stock-news.laohu8.com/highlight/detail?id=2491330809","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491330809?lang=en_us&edition=fundamental","pubTime":"2024-12-13 02:07","pubTimestamp":1734026840,"startTime":"0","endTime":"0","summary":"Aptevo Therapeutics  shares slumped nearly 34% in recent trading Thursday after the company announced the exercise of its warrants at a discount.Holders of the company's previously issued warrants agreed to exercise the securities for 823,544 shares at $7.50 apiece, netting Aptevo $6.2 million in gross proceeds.Aptevo will also issue new warrants to the investors to buy up to 1,647,088 shares at an exercise price of $9.53, it said.Aptevo said it will use the funds for working capital and general corporate purposes. The offering is expected to close by Friday.Price: 6.65, Change: -3.36, Percent Change: -33.57","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["APVO","BK4139"],"gpt_icon":0},{"id":"2491941353","title":"Aptevo Therapeutics Announces Exercise of Warrants for  $6.2 Million Gross Proceeds","url":"https://stock-news.laohu8.com/highlight/detail?id=2491941353","media":"ACCESSWIRE","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491941353?lang=en_us&edition=fundamental","pubTime":"2024-12-13 01:50","pubTimestamp":1734025800,"startTime":"0","endTime":"0","summary":"SEATTLE, WA / ACCESSWIRE / December 12, 2024 / Aptevo Therapeutics Inc.  , a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR and ADAPTIR-FLEX platform technologies, today announced it has entered into agreements with certain holders of its existing warrants for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 823,544 shares of common stock of the Company originally issued in August 2023, in November 2023, in April 2024, in July 2024 and September 2024, all at a reduced exercise price of $7.50 per share. The shares of common stock issuable upon exercise of the outstanding warrants are registered pursuant to effective registration statements on Form S-1 , on Form S-3 , on Form S-1 , on Form S-1  and on Form S-1 . The aggregate gross proceeds from the exercise of the existing warrants is expected to total approximately $6.2 million, before deducting financial advisory fee","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aptevo-therapeutics-announces-exercise-warrants-175000415.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","APVO"],"gpt_icon":0},{"id":"2490382585","title":"Aptevo Therapeutics Shares Rally After Trial Results Show Complete Remission by Acute Myeloid Leukemia Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2490382585","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490382585?lang=en_us&edition=fundamental","pubTime":"2024-12-12 22:49","pubTimestamp":1734014953,"startTime":"0","endTime":"0","summary":"Aptevo Therapeutics  shares were surging early Thursday after the company said all of the patients with acute myeloid leukemia treated with its mipletamig bispecific antibody achieved remission within 30 days of treatment in a phase 1b trial, including two patients in the cohort who experienced complete remission with 100% elimination of cancer cells.The results build on data from the company's prior trial of the immune-oncology therapeutics platform, where 100% of the frontline patients also achieved remission, it said.The phase 1b/2 dose optimization trial is investigating mipletamig as frontline therapy in up to 39 patients across five dosing levels in combination with venetoclax and azacitidine, which are the current standard of care for acute myeloid leukemia.Price: 11.99, Change: +1.98, Percent Change: +19.78","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["APVO","BK4139"],"gpt_icon":0},{"id":"2490384939","title":"Aptevo Therapeutics trading halted, volatility trading pause","url":"https://stock-news.laohu8.com/highlight/detail?id=2490384939","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490384939?lang=en_us&edition=fundamental","pubTime":"2024-12-12 22:35","pubTimestamp":1734014108,"startTime":"0","endTime":"0","summary":"09:33 EST Aptevo Therapeutics (APVO) trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, market...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aptevo-therapeutics-trading-halted-volatility-trading-pause-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aptevo-therapeutics-trading-halted-volatility-trading-pause-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","APVO"],"gpt_icon":0},{"id":"2490815913","title":"Aptevo Therapeutics announces results from cohort 1 in frontline AML trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2490815913","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490815913?lang=en_us&edition=fundamental","pubTime":"2024-12-12 22:15","pubTimestamp":1734012917,"startTime":"0","endTime":"0","summary":"Aptevo Therapeutics (APVO) announced 100% of patients achieved remission within 30 days, in Cohort 1 of the RAINIER frontline acute myeloid leukemi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aptevo-therapeutics-announces-results-from-cohort-1-in-frontline-aml-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aptevo-therapeutics-announces-results-from-cohort-1-in-frontline-aml-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["APVO","BK4139"],"gpt_icon":0},{"id":"2490138759","title":"100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2490138759","media":"ACCESSWIRE","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490138759?lang=en_us&edition=fundamental","pubTime":"2024-12-12 22:00","pubTimestamp":1734012000,"startTime":"0","endTime":"0","summary":"Two of three patients achieved both complete remission and MRD-negative status. High response rates observed in earlier studies continue in ongoing mipletamig trial. \"Achieving remission in all three Cohort 1 patients is highly encouraging, particularly when viewed alongside prior trial results. Notably, two of these three patients achieved MRD-negative status, a critical outcome indicating that even the most sensitive diagnostic methods detect no remaining cancer cells. This result is strongly associated with longer-lasting remissions and improved survival rates,\" said Dirk Huebner, MD, Chief Medical Officer at Aptevo. \"What makes these outcomes even more compelling is that one of the MRD-negative patients had a TP53 mutation, a subgroup known for its poor prognosis due to chemotherapy resistance, genetic instability, and overall treatment challenges. This growing body of data underscores mipletamig's p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/100-patients-achieve-remission-within-140000631.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4161","BK4139","APVO","CR"],"gpt_icon":0},{"id":"2488995471","title":"BRIEF-Aptevo Therapeutics Announces Details On Preclinical Bispecific Antibody APVO442","url":"https://stock-news.laohu8.com/highlight/detail?id=2488995471","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488995471?lang=en_us&edition=fundamental","pubTime":"2024-12-04 21:53","pubTimestamp":1733320400,"startTime":"0","endTime":"0","summary":"BRIEF-Aptevo Therapeutics Announces Details On Preclinical Bispecific Antibody APVO442Dec 4  - Aptevo Therapeutics Inc APVO.O:APTEVO THERAPEUTICS INC - ANNOUNCES DETAILS ON PRECLINICAL BISPECIFIC ANTIBODY APVO442Source text: [ID:n0000950170-24-133091]Further company coverage: APVO.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241204:nFWN3N418C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APVO"],"gpt_icon":0},{"id":"2488196073","title":"Aptevo Therapeutics Inc - Announces Details on Preclinical Bispecific Antibody Apvo442","url":"https://stock-news.laohu8.com/highlight/detail?id=2488196073","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488196073?lang=en_us&edition=fundamental","pubTime":"2024-12-04 21:47","pubTimestamp":1733320026,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241204:nFWN3N418C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["APVO","BK4139"],"gpt_icon":0},{"id":"2488199023","title":"Aptevo Therapeutics announces additional details about APVO442","url":"https://stock-news.laohu8.com/highlight/detail?id=2488199023","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488199023?lang=en_us&edition=fundamental","pubTime":"2024-12-04 21:45","pubTimestamp":1733319948,"startTime":"0","endTime":"0","summary":"Aptevo Therapeutics (APVO) announced additional details about the Company’s preclinical bispecific antibody, APVO442, differentiated to target pros...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aptevo-therapeutics-announces-additional-details-about-apvo442?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aptevo-therapeutics-announces-additional-details-about-apvo442?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","APVO"],"gpt_icon":0},{"id":"2488510194","title":"Bispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects","url":"https://stock-news.laohu8.com/highlight/detail?id=2488510194","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488510194?lang=en_us&edition=fundamental","pubTime":"2024-12-04 21:35","pubTimestamp":1733319300,"startTime":"0","endTime":"0","summary":"Powered by Aptevo's proprietary ADAPTIR-FLEXplatform, antibody innovation targeting difficult-to-treat cancers. \"We are excited about APVO442, our PSMA x CD3 bispecific, designed using our ADAPTIR-FLEX platform. By designing a therapeutic that binds to two different antigens present on prostate cancer and immune cells, the treatment becomes more selective, reducing the likelihood of affecting healthy cells and increasing its anti-cancer potential. The engagement of CD3 amplifies the immune response, making it an ideal candidate for combination therapy and even greater efficacy. We anticipate that the safety and efficacy advantages of APVO442 will be confirmed in the clinic, following the positive overall performance of our other CD3-targeting clinical candidate, mipletamig,\" said Marvin White, President and CEO of Aptevo. \"The global prostate cancer market, currently valued at $14 billion, is projected to grow to $24 billion over the next decade. While survival rates have improved sign","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bispecific-antibody-apvo442-differentiated-treat-133500711.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["APVO","BK4139"],"gpt_icon":1}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":46}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/APVO\",params:#limit:5,,,undefined,":[{"date":"2025-02-14","symbol":"APVO","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1739523600000,"name":null,"time":"Pre-Market","dateTimestamp":1739509200000,"actualEps":null},{"market":"US","date":"2024-12-04","symbol":"APVO","defaultRemindTime":1733322600000,"type":"split","dateTimestamp":1733288400000,"forFactor":37,"toFactor":1,"ratio":37},{"market":"US","date":"2024-11-07","symbol":"APVO","fiscalQuarterEnding":"2024/09","expectedEps":-0.57,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"pre","actualEps":-0.48},{"market":"US","date":"2024-08-08","symbol":"APVO","fiscalQuarterEnding":"2024/06","expectedEps":-1.93,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723089600000,"reportTimeType":"pre","actualEps":-1.67},{"market":"US","date":"2024-05-08","symbol":"APVO","fiscalQuarterEnding":"2024/03","expectedEps":-14.1,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715140800000,"reportTimeType":"pre","actualEps":-9.95}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"APVO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"APVO\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1696910400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/APVO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"APVO","date":"2025-03-31","current":-0.067694,"percent":0.772727,"low":-10.622263,"twenty":-2.459807,"median":-0.255606,"eighty":0.262505,"high":3.317157,"avg":-1.129847,"sd":2.733574,"marketCap":1633458},"quantilePoints":[{"date":"2020-04-03","current":-0.248676,"twenty":-0.788054,"median":-0.655053,"eighty":14.257552,"marketCap":10058449},{"date":"2020-04-09","current":-0.30704,"twenty":-0.788054,"median":-0.653053,"eighty":14.231805,"marketCap":12419155},{"date":"2020-04-17","current":-0.316635,"twenty":-0.78788,"median":-0.651279,"eighty":14.122379,"marketCap":12807253},{"date":"2020-04-24","current":-0.342222,"twenty":-0.787635,"median":-0.647941,"eighty":14.045137,"marketCap":13842183},{"date":"2020-05-01","current":-0.419781,"twenty":-0.786474,"median":-0.647742,"eighty":14.006516,"marketCap":16979313},{"date":"2020-05-08","current":-0.502938,"twenty":-0.786196,"median":-0.647364,"eighty":13.974332,"marketCap":20342834},{"date":"2020-05-15","current":-0.692573,"twenty":-0.786196,"median":-0.647396,"eighty":13.813411,"marketCap":17683476},{"date":"2020-05-22","current":-0.822985,"twenty":-0.786196,"median":-0.64765,"eighty":13.77479,"marketCap":21013271},{"date":"2020-05-29","current":-0.721694,"twenty":-0.786196,"median":-0.647941,"eighty":13.658928,"marketCap":18427022},{"date":"2020-06-05","current":-0.730557,"twenty":-0.785096,"median":-0.650558,"eighty":13.562376,"marketCap":18653319},{"date":"2020-06-12","current":-0.681178,"twenty":-0.786196,"median":-0.652052,"eighty":13.530192,"marketCap":17392523},{"date":"2020-06-19","current":-0.769807,"twenty":-0.785096,"median":-0.654643,"eighty":13.509222,"marketCap":19655490},{"date":"2020-06-26","current":-1.038227,"twenty":-0.786196,"median":-0.655934,"eighty":13.503825,"marketCap":26509050},{"date":"2020-07-02","current":-1.162308,"twenty":-0.787967,"median":-0.656676,"eighty":13.496349,"marketCap":29677204},{"date":"2020-07-10","current":-0.973654,"twenty":-0.788324,"median":-0.658898,"eighty":13.395018,"marketCap":24860316},{"date":"2020-07-17","current":-0.992646,"twenty":-0.791378,"median":-0.65946,"eighty":13.175771,"marketCap":25345238},{"date":"2020-07-24","current":-1.020501,"twenty":-0.793706,"median":-0.660268,"eighty":13.03755,"marketCap":26056456},{"date":"2020-07-31","current":-1.06355,"twenty":-0.797409,"median":-0.661301,"eighty":12.777162,"marketCap":27155612},{"date":"2020-08-07","current":-1.06988,"twenty":-0.801094,"median":-0.661477,"eighty":12.038388,"marketCap":27317252},{"date":"2020-08-14","current":-1.355794,"twenty":-0.804169,"median":-0.662186,"eighty":11.463113,"marketCap":25765503},{"date":"2020-08-21","current":-1.495286,"twenty":-0.808908,"median":-0.663688,"eighty":11.021059,"marketCap":28416408},{"date":"2020-08-28","current":-1.372805,"twenty":-0.81215,"median":-0.663922,"eighty":10.324675,"marketCap":26088784},{"date":"2020-09-04","current":-1.337081,"twenty":-0.816597,"median":-0.664991,"eighty":10.209623,"marketCap":25409894},{"date":"2020-09-11","current":-1.279243,"twenty":-0.818533,"median":-0.665547,"eighty":10.136956,"marketCap":24310738},{"date":"2020-09-18","current":-1.326875,"twenty":-0.826968,"median":-0.66627,"eighty":9.979509,"marketCap":25215925},{"date":"2020-09-25","current":-1.240117,"twenty":-0.835327,"median":-0.667339,"eighty":9.894732,"marketCap":23567192},{"date":"2020-10-02","current":-1.306461,"twenty":-0.839016,"median":-0.668655,"eighty":9.737292,"marketCap":24827988},{"date":"2020-10-09","current":-1.219704,"twenty":-0.845781,"median":-0.671339,"eighty":9.67068,"marketCap":23179254},{"date":"2020-10-16","current":-1.187383,"twenty":-0.850697,"median":-0.673566,"eighty":9.537456,"marketCap":22565020},{"date":"2020-10-23","current":-1.192486,"twenty":-0.855424,"median":-0.675811,"eighty":9.283127,"marketCap":22662005},{"date":"2020-10-30","current":-1.098924,"twenty":-0.864478,"median":-0.677891,"eighty":9.222572,"marketCap":20883959},{"date":"2020-11-06","current":-4.031658,"twenty":-0.87135,"median":-0.678444,"eighty":9.174128,"marketCap":76617620},{"date":"2020-11-13","current":-9.879847,"twenty":-0.88165,"median":-0.679314,"eighty":9.14385,"marketCap":186442594},{"date":"2020-11-20","current":-10.022619,"twenty":-0.893651,"median":-0.681918,"eighty":9.010628,"marketCap":189136851},{"date":"2020-11-27","current":-9.750254,"twenty":-0.903209,"median":-0.68286,"eighty":8.962184,"marketCap":183997038},{"date":"2020-12-04","current":-10.040191,"twenty":-0.911128,"median":-0.684423,"eighty":8.841074,"marketCap":189468452},{"date":"2020-12-11","current":-9.673376,"twenty":-0.915089,"median":-0.685404,"eighty":8.659408,"marketCap":182546284},{"date":"2020-12-18","current":-9.286097,"twenty":-0.920713,"median":-0.686941,"eighty":-0.229314,"marketCap":175237935},{"date":"2020-12-24","current":-8.214089,"twenty":-0.930237,"median":-0.687053,"eighty":-0.240945,"marketCap":155008068},{"date":"2020-12-31","current":-8.504134,"twenty":-0.934298,"median":-0.68952,"eighty":-0.246747,"marketCap":160481517},{"date":"2021-01-08","current":-8.680482,"twenty":-0.939914,"median":-0.692779,"eighty":-0.249588,"marketCap":163809374},{"date":"2021-01-15","current":-7.543504,"twenty":-0.949851,"median":-0.695822,"eighty":-0.253592,"marketCap":142353455},{"date":"2021-01-22","current":-7.784821,"twenty":-0.957365,"median":-0.69645,"eighty":-0.257462,"marketCap":146907364},{"date":"2021-01-29","current":-7.77322,"twenty":-0.965363,"median":-0.696821,"eighty":-0.26083,"marketCap":146688426},{"date":"2021-02-05","current":-8.186244,"twenty":-0.973225,"median":-0.697564,"eighty":-0.263229,"marketCap":154482617},{"date":"2021-02-12","current":-8.587667,"twenty":-0.98926,"median":-0.700307,"eighty":-0.266139,"marketCap":162057870},{"date":"2021-02-19","current":-8.374194,"twenty":-0.993238,"median":-0.70187,"eighty":-0.268444,"marketCap":158029412},{"date":"2021-02-26","current":-7.589911,"twenty":-1.001287,"median":-0.70338,"eighty":-0.269322,"marketCap":143229206},{"date":"2021-03-05","current":-7.536542,"twenty":-1.009777,"median":-0.704572,"eighty":-0.271644,"marketCap":142222092},{"date":"2021-03-12","current":-8.346349,"twenty":-1.013174,"median":-0.707049,"eighty":-0.274953,"marketCap":157503961},{"date":"2021-03-19","current":-7.875316,"twenty":-1.02385,"median":-0.708187,"eighty":-0.282521,"marketCap":148615080},{"date":"2021-03-26","current":-6.845074,"twenty":-1.029596,"median":-0.71031,"eighty":-0.285066,"marketCap":129173390},{"date":"2021-04-01","current":-7.096515,"twenty":-1.036961,"median":-0.710664,"eighty":-0.291055,"marketCap":125963136},{"date":"2021-04-09","current":-6.429728,"twenty":-1.044836,"median":-0.712614,"eighty":-0.291848,"marketCap":114127674},{"date":"2021-04-16","current":-6.347006,"twenty":-1.048794,"median":-0.713774,"eighty":-0.295853,"marketCap":112659365},{"date":"2021-04-23","current":-6.399647,"twenty":-1.052752,"median":-0.714717,"eighty":-0.299148,"marketCap":113593743},{"date":"2021-04-30","current":-6.69544,"twenty":-1.057219,"median":-0.717239,"eighty":-0.305441,"marketCap":118844061},{"date":"2021-05-07","current":-5.915851,"twenty":-1.06355,"median":-0.717239,"eighty":-0.30628,"marketCap":105006359},{"date":"2021-05-14","current":-3.654924,"twenty":-1.06988,"median":-0.71881,"eighty":-0.30704,"marketCap":101983342},{"date":"2021-05-21","current":-4.045612,"twenty":-1.077477,"median":-0.720566,"eighty":-0.308639,"marketCap":112884702},{"date":"2021-05-28","current":-4.16521,"twenty":-1.085074,"median":-0.720979,"eighty":-0.311038,"marketCap":116221854},{"date":"2021-06-04","current":-4.18594,"twenty":-1.089467,"median":-0.720979,"eighty":-0.315516,"marketCap":116800293},{"date":"2021-06-11","current":-4.119763,"twenty":-1.099941,"median":-0.722931,"eighty":-0.317754,"marketCap":114953736},{"date":"2021-06-18","current":-4.362946,"twenty":-1.110102,"median":-0.724861,"eighty":-0.31884,"marketCap":121739277},{"date":"2021-06-25","current":-3.973853,"twenty":-1.122632,"median":-0.725492,"eighty":-0.320315,"marketCap":110882412},{"date":"2021-07-02","current":-3.415727,"twenty":-1.134735,"median":-0.726043,"eighty":-0.329595,"marketCap":95309039},{"date":"2021-07-09","current":-3.511406,"twenty":-1.144489,"median":-0.727014,"eighty":-0.331857,"marketCap":97978760},{"date":"2021-07-16","current":-3.020256,"twenty":-1.160845,"median":-0.727634,"eighty":-0.333284,"marketCap":84274192},{"date":"2021-07-23","current":-3.288953,"twenty":-1.173703,"median":-0.728025,"eighty":-0.336476,"marketCap":91771659},{"date":"2021-07-30","current":-2.993147,"twenty":-1.188744,"median":-0.728605,"eighty":-0.340524,"marketCap":83517771},{"date":"2021-08-06","current":-3.004309,"twenty":-1.195229,"median":-0.728948,"eighty":-0.342222,"marketCap":83829239},{"date":"2021-08-13","current":-2.865729,"twenty":-1.19844,"median":-0.728948,"eighty":-0.342222,"marketCap":83197847},{"date":"2021-08-20","current":-2.889329,"twenty":-1.199291,"median":-0.728948,"eighty":-0.342222,"marketCap":83883005},{"date":"2021-08-27","current":-2.963501,"twenty":-1.209157,"median":-0.729291,"eighty":-0.342703,"marketCap":86036361},{"date":"2021-09-03","current":-3.059587,"twenty":-1.225828,"median":-0.729291,"eighty":-0.342703,"marketCap":88825936},{"date":"2021-09-10","current":-2.887643,"twenty":-1.246922,"median":-0.729291,"eighty":-0.342703,"marketCap":83834065},{"date":"2021-09-17","current":-2.909558,"twenty":-1.295574,"median":-0.729291,"eighty":-0.342703,"marketCap":84470284},{"date":"2021-09-24","current":-2.823586,"twenty":-1.309523,"median":-0.729291,"eighty":-0.342703,"marketCap":81974349},{"date":"2021-10-01","current":-2.639842,"twenty":-1.31973,"median":-0.729291,"eighty":-0.342703,"marketCap":76639899},{"date":"2021-10-08","current":-2.444298,"twenty":-1.342525,"median":-0.729291,"eighty":-0.342703,"marketCap":70962869},{"date":"2021-10-15","current":-2.526899,"twenty":-1.370424,"median":-0.729291,"eighty":-0.342703,"marketCap":73360925},{"date":"2021-10-22","current":-2.402155,"twenty":-1.429717,"median":-0.729291,"eighty":-0.342703,"marketCap":69739371},{"date":"2021-10-29","current":-2.569042,"twenty":-1.507874,"median":-0.729291,"eighty":-0.342703,"marketCap":74584422},{"date":"2021-11-05","current":-2.793243,"twenty":-2.429127,"median":-0.729291,"eighty":-0.342703,"marketCap":81093430},{"date":"2021-11-12","current":-1.949966,"twenty":-2.43823,"median":-0.729291,"eighty":-0.342703,"marketCap":57013115},{"date":"2021-11-19","current":-1.222917,"twenty":-2.43823,"median":-0.729291,"eighty":-0.342703,"marketCap":35755648},{"date":"2021-11-26","current":-2.189524,"twenty":-2.441939,"median":-0.729291,"eighty":-0.342703,"marketCap":64017304},{"date":"2021-12-03","current":-1.177686,"twenty":-2.441939,"median":-0.729291,"eighty":-0.342703,"marketCap":34433179},{"date":"2021-12-10","current":-1.301653,"twenty":-2.441939,"median":-0.729291,"eighty":-0.342703,"marketCap":38057724},{"date":"2021-12-17","current":-1.360286,"twenty":-2.441939,"median":-0.729433,"eighty":-0.342703,"marketCap":39772036},{"date":"2021-12-23","current":-1.318405,"twenty":-2.441939,"median":-0.729433,"eighty":-0.342703,"marketCap":38547527},{"date":"2021-12-31","current":-1.318405,"twenty":-2.441939,"median":-0.729433,"eighty":-0.342703,"marketCap":38547527},{"date":"2022-01-07","current":-1.237994,"twenty":-2.441264,"median":-0.729433,"eighty":-0.343184,"marketCap":36196471},{"date":"2022-01-14","current":-1.209565,"twenty":-2.441264,"median":-0.729433,"eighty":-0.343184,"marketCap":35365274},{"date":"2022-01-21","current":-0.98671,"twenty":-2.441264,"median":-0.729433,"eighty":-0.343184,"marketCap":28849420},{"date":"2022-01-28","current":-0.909649,"twenty":-2.44059,"median":-0.729433,"eighty":-0.343666,"marketCap":26596324},{"date":"2022-02-04","current":-0.934778,"twenty":-2.44059,"median":-0.729433,"eighty":-0.343666,"marketCap":27331029},{"date":"2022-02-11","current":-0.985035,"twenty":-2.439915,"median":-0.729433,"eighty":-0.344147,"marketCap":28800439},{"date":"2022-02-18","current":-0.967608,"twenty":-2.439915,"median":-0.729433,"eighty":-0.344147,"marketCap":28290911},{"date":"2022-02-25","current":-0.974458,"twenty":-2.439915,"median":-0.729433,"eighty":-0.344147,"marketCap":28491201},{"date":"2022-03-04","current":-0.907667,"twenty":-2.439915,"median":-0.729433,"eighty":-0.344147,"marketCap":26538377},{"date":"2022-03-11","current":-0.813475,"twenty":-2.439915,"median":-0.730884,"eighty":-0.344147,"marketCap":23784394},{"date":"2022-03-18","current":-0.869991,"twenty":-2.439915,"median":-0.731099,"eighty":-0.344147,"marketCap":25436784},{"date":"2022-03-25","current":-1.068066,"twenty":-2.439915,"median":-0.731664,"eighty":-0.344147,"marketCap":30393952},{"date":"2022-04-01","current":-1.108536,"twenty":-2.439915,"median":-0.732068,"eighty":-0.344147,"marketCap":31545618},{"date":"2022-04-08","current":-0.948414,"twenty":-2.439915,"median":-0.733014,"eighty":-0.344147,"marketCap":26989028},{"date":"2022-04-14","current":-0.837561,"twenty":-2.439915,"median":-0.735904,"eighty":-0.344147,"marketCap":23834467},{"date":"2022-04-22","current":-0.823484,"twenty":-2.439915,"median":-0.738671,"eighty":-0.344147,"marketCap":23433887},{"date":"2022-04-29","current":-0.749582,"twenty":-2.439915,"median":-0.739917,"eighty":-0.344147,"marketCap":21330846},{"date":"2022-05-06","current":-0.710871,"twenty":-2.439915,"median":-0.740753,"eighty":-0.344147,"marketCap":20229253},{"date":"2022-05-13","current":-0.797056,"twenty":-2.439915,"median":-0.741669,"eighty":-0.344147,"marketCap":23033313},{"date":"2022-05-20","current":-0.788392,"twenty":-2.439915,"median":-0.744513,"eighty":-0.344147,"marketCap":22782951},{"date":"2022-05-27","current":-0.845572,"twenty":-2.439915,"median":-0.74549,"eighty":-0.344147,"marketCap":24435340},{"date":"2022-06-03","current":-0.864632,"twenty":-2.439915,"median":-0.745907,"eighty":-0.344147,"marketCap":24986137},{"date":"2022-06-10","current":-0.689626,"twenty":-2.439915,"median":-0.748131,"eighty":-0.344147,"marketCap":19928823},{"date":"2022-06-17","current":-0.60299,"twenty":-2.439915,"median":-0.747837,"eighty":-0.344147,"marketCap":17425202},{"date":"2022-06-24","current":-0.672299,"twenty":-2.44059,"median":-0.745751,"eighty":-0.343666,"marketCap":19428098},{"date":"2022-07-01","current":-0.620317,"twenty":-2.44059,"median":-0.745306,"eighty":-0.343666,"marketCap":17925926},{"date":"2022-07-08","current":-0.722548,"twenty":-2.44059,"median":-0.745306,"eighty":-0.343666,"marketCap":20880199},{"date":"2022-07-15","current":-0.67923,"twenty":-2.44059,"median":-0.745306,"eighty":-0.343666,"marketCap":19628388},{"date":"2022-07-22","current":-0.696557,"twenty":-2.44059,"median":-0.745673,"eighty":-0.343666,"marketCap":20129112},{"date":"2022-07-29","current":-0.682695,"twenty":-2.44059,"median":-0.745673,"eighty":-0.343666,"marketCap":19728533},{"date":"2022-08-05","current":-0.743341,"twenty":-2.44059,"median":-0.745673,"eighty":-0.343666,"marketCap":21481068},{"date":"2022-08-12","current":3.1943,"twenty":-2.44059,"median":-0.746063,"eighty":-0.336476,"marketCap":22500646},{"date":"2022-08-19","current":2.478834,"twenty":-2.44059,"median":-0.746063,"eighty":-0.318638,"marketCap":17460908},{"date":"2022-08-26","current":2.616146,"twenty":-2.44059,"median":-0.746063,"eighty":-0.306736,"marketCap":18428131},{"date":"2022-09-02","current":2.579939,"twenty":-2.44059,"median":-0.746063,"eighty":-0.291531,"marketCap":18173090},{"date":"2022-09-09","current":2.764298,"twenty":-2.44059,"median":-0.745751,"eighty":-0.272385,"marketCap":19471713},{"date":"2022-09-16","current":2.587238,"twenty":-2.44059,"median":-0.745751,"eighty":-0.261309,"marketCap":18224505},{"date":"2022-09-23","current":2.2548,"twenty":-2.44059,"median":-0.745751,"eighty":-0.238037,"marketCap":15882809},{"date":"2022-09-30","current":2.196984,"twenty":-2.44059,"median":-0.744541,"eighty":2.2548,"marketCap":15475557},{"date":"2022-10-07","current":2.124715,"twenty":-2.44059,"median":-0.743341,"eighty":2.260582,"marketCap":14966493},{"date":"2022-10-14","current":2.045219,"twenty":-2.44059,"median":-0.739917,"eighty":2.260582,"marketCap":14406522},{"date":"2022-10-21","current":2.059673,"twenty":-2.44059,"median":-0.737228,"eighty":2.260582,"marketCap":14508335},{"date":"2022-10-28","current":2.16085,"twenty":-2.44059,"median":-0.733054,"eighty":2.260582,"marketCap":15221025},{"date":"2022-11-04","current":2.074127,"twenty":-2.44059,"median":-0.730668,"eighty":2.260582,"marketCap":14610148},{"date":"2022-11-11","current":2.507275,"twenty":-2.44059,"median":-0.728605,"eighty":2.298162,"marketCap":16039037},{"date":"2022-11-18","current":2.483396,"twenty":-2.44059,"median":-0.728605,"eighty":2.476795,"marketCap":15886284},{"date":"2022-11-25","current":2.316244,"twenty":-2.44059,"median":-0.728605,"eighty":2.476795,"marketCap":14817015},{"date":"2022-12-02","current":2.467556,"twenty":-2.44059,"median":-0.728605,"eighty":2.478834,"marketCap":15784958},{"date":"2022-12-09","current":2.764529,"twenty":-2.44059,"median":-0.728025,"eighty":2.519025,"marketCap":17684693},{"date":"2022-12-16","current":1.719274,"twenty":-2.44059,"median":-0.727014,"eighty":2.542431,"marketCap":10998197},{"date":"2022-12-23","current":1.647638,"twenty":-2.44059,"median":-0.722548,"eighty":2.542431,"marketCap":10539939},{"date":"2022-12-30","current":1.846628,"twenty":-2.44059,"median":-0.719816,"eighty":2.542431,"marketCap":11812878},{"date":"2023-01-06","current":1.735193,"twenty":-2.44059,"median":-0.719816,"eighty":2.483396,"marketCap":11100032},{"date":"2023-01-13","current":1.790911,"twenty":-2.44059,"median":-0.719816,"eighty":2.467509,"marketCap":11456455},{"date":"2023-01-20","current":1.910305,"twenty":-2.44059,"median":-0.719816,"eighty":2.407217,"marketCap":12220219},{"date":"2023-01-27","current":1.902345,"twenty":-2.44059,"median":-0.719816,"eighty":2.306693,"marketCap":12169301},{"date":"2023-02-03","current":1.703355,"twenty":-2.44059,"median":-0.719816,"eighty":2.257091,"marketCap":10896362},{"date":"2023-02-10","current":1.679476,"twenty":-2.44059,"median":-0.719816,"eighty":2.192648,"marketCap":10743609},{"date":"2023-02-17","current":1.587383,"twenty":-2.44059,"median":-0.719816,"eighty":2.166632,"marketCap":10154492},{"date":"2023-02-24","current":1.59988,"twenty":-2.44059,"median":-0.719816,"eighty":2.134833,"marketCap":10234433},{"date":"2023-03-03","current":1.711315,"twenty":-2.44059,"median":-0.719816,"eighty":2.103034,"marketCap":10947279},{"date":"2023-03-10","current":1.480486,"twenty":-2.44059,"median":-0.719816,"eighty":2.062564,"marketCap":9470669},{"date":"2023-03-17","current":1.40885,"twenty":-2.44059,"median":-0.719816,"eighty":2.025349,"marketCap":9012411},{"date":"2023-03-24","current":1.472526,"twenty":-2.44059,"median":-0.719816,"eighty":1.93461,"marketCap":9419752},{"date":"2023-03-31","current":1.639331,"twenty":-2.439915,"median":-0.71945,"eighty":1.902345,"marketCap":13158908},{"date":"2023-04-06","current":1.474189,"twenty":-2.439915,"median":-0.71945,"eighty":1.846628,"marketCap":11833318},{"date":"2023-04-14","current":1.704572,"twenty":-2.44059,"median":-0.719816,"eighty":1.817973,"marketCap":13682600},{"date":"2023-04-21","current":1.650459,"twenty":-2.44059,"median":-0.719816,"eighty":1.790911,"marketCap":13248231},{"date":"2023-04-28","current":1.777625,"twenty":-2.44059,"median":-0.719816,"eighty":1.741561,"marketCap":14268997},{"date":"2023-05-05","current":1.56027,"twenty":-2.44059,"median":-0.719816,"eighty":1.719274,"marketCap":12524284},{"date":"2023-05-12","current":1.524194,"twenty":-2.44059,"median":-0.719816,"eighty":1.711315,"marketCap":12234705},{"date":"2023-05-19","current":0.661443,"twenty":-2.44059,"median":-0.719816,"eighty":1.695553,"marketCap":12234705},{"date":"2023-05-26","current":0.642423,"twenty":-2.44059,"median":-0.719816,"eighty":1.682299,"marketCap":11882897},{"date":"2023-06-02","current":0.618775,"twenty":-2.44059,"median":-0.719816,"eighty":1.671516,"marketCap":11445489},{"date":"2023-06-09","current":0.63454,"twenty":-2.44059,"median":-0.719816,"eighty":1.655597,"marketCap":11737094},{"date":"2023-06-16","current":0.630599,"twenty":-2.44059,"median":-0.719816,"eighty":1.642208,"marketCap":11664193},{"date":"2023-06-23","current":0.563598,"twenty":-2.441264,"median":-0.720122,"eighty":1.63214,"marketCap":10424873},{"date":"2023-06-30","current":0.571481,"twenty":-2.441939,"median":-0.720428,"eighty":1.615799,"marketCap":10570675},{"date":"2023-07-07","current":0.591379,"twenty":-2.441939,"median":-0.720428,"eighty":1.599173,"marketCap":10938742},{"date":"2023-07-14","current":0.636199,"twenty":-2.441939,"median":-0.720428,"eighty":1.586653,"marketCap":11767766},{"date":"2023-07-21","current":0.428256,"twenty":-2.441939,"median":-0.720428,"eighty":1.558393,"marketCap":7921442},{"date":"2023-07-28","current":0.424177,"twenty":-2.441939,"median":-0.720428,"eighty":1.502919,"marketCap":7846000},{"date":"2023-08-04","current":0.244717,"twenty":-2.441939,"median":-0.720428,"eighty":1.479227,"marketCap":4526538},{"date":"2023-08-11","current":-0.252576,"twenty":-2.441939,"median":-0.720428,"eighty":1.43432,"marketCap":4410226},{"date":"2023-08-18","current":-0.276461,"twenty":-2.441939,"median":-0.720428,"eighty":0.723408,"marketCap":4827284},{"date":"2023-08-25","current":-0.254418,"twenty":-2.441939,"median":-0.720428,"eighty":0.661992,"marketCap":4442392},{"date":"2023-09-01","current":-0.290386,"twenty":-2.441939,"median":-0.720428,"eighty":0.646249,"marketCap":5070435},{"date":"2023-09-08","current":-0.263988,"twenty":-2.441939,"median":-0.720428,"eighty":0.635867,"marketCap":4609486},{"date":"2023-09-15","current":-0.257586,"twenty":-2.441939,"median":-0.720428,"eighty":0.630506,"marketCap":4497706},{"date":"2023-09-22","current":-0.22109,"twenty":-2.441939,"median":-0.720428,"eighty":0.622717,"marketCap":3860444},{"date":"2023-09-29","current":-0.20822,"twenty":-2.441939,"median":-0.720428,"eighty":0.609249,"marketCap":3635732},{"date":"2023-10-06","current":-0.20921,"twenty":-2.441939,"median":-0.720428,"eighty":0.582476,"marketCap":3653017},{"date":"2023-10-13","current":-0.250788,"twenty":-2.441939,"median":-0.720428,"eighty":0.560099,"marketCap":4379012},{"date":"2023-10-20","current":-0.227029,"twenty":-2.441939,"median":-0.720428,"eighty":0.442123,"marketCap":3964158},{"date":"2023-10-27","current":-0.213299,"twenty":-2.443287,"median":-0.721556,"eighty":0.424177,"marketCap":3724407},{"date":"2023-11-03","current":-0.177598,"twenty":-2.443287,"median":-0.721556,"eighty":0.331961,"marketCap":3101031},{"date":"2023-11-10","current":-0.153773,"twenty":-2.443287,"median":-0.721556,"eighty":0.245484,"marketCap":2685025},{"date":"2023-11-17","current":-0.129865,"twenty":-2.443287,"median":-0.71945,"eighty":-0.117527,"marketCap":2097316},{"date":"2023-11-24","current":-0.209929,"twenty":-2.443287,"median":-0.713851,"eighty":-0.117527,"marketCap":3390347},{"date":"2023-12-01","current":-0.203984,"twenty":-2.443287,"median":-0.709909,"eighty":-0.117527,"marketCap":3294336},{"date":"2023-12-08","current":-0.210201,"twenty":-2.44295,"median":-0.705221,"eighty":-0.117764,"marketCap":3394751},{"date":"2023-12-15","current":-0.191985,"twenty":-2.44295,"median":-0.698297,"eighty":-0.117764,"marketCap":3100551},{"date":"2023-12-22","current":-0.201802,"twenty":-2.44295,"median":-0.696557,"eighty":-0.117764,"marketCap":3259102},{"date":"2023-12-29","current":-0.206602,"twenty":-2.443287,"median":-0.696557,"eighty":-0.117527,"marketCap":3336616},{"date":"2024-01-05","current":-0.206134,"twenty":-2.443624,"median":-0.696557,"eighty":-0.117289,"marketCap":3329059},{"date":"2024-01-12","current":-0.185952,"twenty":-2.443624,"median":-0.693423,"eighty":-0.117289,"marketCap":3003124},{"date":"2024-01-19","current":-0.211307,"twenty":-2.443961,"median":-0.688725,"eighty":-0.117052,"marketCap":3412604},{"date":"2024-01-26","current":-0.214349,"twenty":-2.443624,"median":-0.687824,"eighty":-0.117289,"marketCap":3461738},{"date":"2024-02-02","current":-0.211583,"twenty":-2.443624,"median":-0.686966,"eighty":-0.117289,"marketCap":3417070},{"date":"2024-02-09","current":-0.203286,"twenty":-2.443624,"median":-0.683062,"eighty":-0.117289,"marketCap":3283068},{"date":"2024-02-16","current":-0.217115,"twenty":-2.443624,"median":-0.67923,"eighty":-0.117289,"marketCap":3506405},{"date":"2024-02-23","current":-0.192223,"twenty":-2.443624,"median":-0.678183,"eighty":-0.117289,"marketCap":3104397},{"date":"2024-03-01","current":-0.235093,"twenty":-2.443287,"median":-0.675863,"eighty":-0.117527,"marketCap":3796745},{"date":"2024-03-08","current":-0.202221,"twenty":-2.443287,"median":-0.67223,"eighty":-0.117527,"marketCap":3520869},{"date":"2024-03-15","current":-0.154423,"twenty":-2.443287,"median":-0.667339,"eighty":-0.117527,"marketCap":2688663},{"date":"2024-03-22","current":-0.137265,"twenty":-2.443287,"median":-0.664222,"eighty":-0.117527,"marketCap":2389923},{"date":"2024-03-28","current":-0.124396,"twenty":-2.443287,"median":-0.663546,"eighty":-0.117527,"marketCap":2165867},{"date":"2024-04-05","current":-0.1054,"twenty":-2.443624,"median":-0.659831,"eighty":-0.109812,"marketCap":1835119},{"date":"2024-04-12","current":-0.029353,"twenty":-2.443624,"median":-0.653239,"eighty":-0.047026,"marketCap":511059},{"date":"2024-04-19","current":-0.064574,"twenty":-2.443624,"median":-0.647364,"eighty":-0.041513,"marketCap":1124300},{"date":"2024-04-26","current":-0.062756,"twenty":-2.443287,"median":-0.646527,"eighty":-0.047466,"marketCap":1092647},{"date":"2024-05-03","current":-0.104286,"twenty":-2.443287,"median":-0.646527,"eighty":-0.047466,"marketCap":1815723},{"date":"2024-05-10","current":-0.055607,"twenty":-2.443287,"median":-0.644437,"eighty":-0.045105,"marketCap":1502390},{"date":"2024-05-17","current":-0.047352,"twenty":-2.443287,"median":-0.641613,"eighty":-0.040152,"marketCap":1279362},{"date":"2024-05-24","current":-0.043409,"twenty":-2.443287,"median":-0.639004,"eighty":-0.037787,"marketCap":1172828},{"date":"2024-05-31","current":-0.043147,"twenty":-2.443287,"median":-0.639004,"eighty":-0.037112,"marketCap":1165758},{"date":"2024-06-07","current":-0.128062,"twenty":-2.443287,"median":-0.635199,"eighty":-0.037112,"marketCap":3459983},{"date":"2024-06-14","current":-0.117944,"twenty":-2.443624,"median":-0.628515,"eighty":-0.034526,"marketCap":3186611},{"date":"2024-06-21","current":-0.081549,"twenty":-2.443961,"median":-0.62588,"eighty":-0.031939,"marketCap":2203291},{"date":"2024-06-28","current":-0.077758,"twenty":-2.445647,"median":-0.620611,"eighty":0.080275,"marketCap":2100879},{"date":"2024-07-05","current":-0.089228,"twenty":-2.445647,"median":-0.617391,"eighty":0.080275,"marketCap":2410765},{"date":"2024-07-12","current":-0.094359,"twenty":-2.445647,"median":-0.614756,"eighty":0.080275,"marketCap":2549403},{"date":"2024-07-15","current":-0.151041,"twenty":-2.445647,"median":-0.61378,"eighty":0.080275,"marketCap":4080820},{"date":"2024-08-02","current":-0.193713,"twenty":-2.457784,"median":-0.604315,"eighty":0.260287,"marketCap":5233726},{"date":"2024-08-09","current":-0.218472,"twenty":-2.457784,"median":-0.601492,"eighty":0.260287,"marketCap":5451527},{"date":"2024-08-16","current":-0.164225,"twenty":-2.457784,"median":-0.596512,"eighty":0.260287,"marketCap":4097912},{"date":"2024-08-23","current":-0.143688,"twenty":-2.457784,"median":-0.5893,"eighty":0.260287,"marketCap":3585438},{"date":"2024-08-30","current":-0.13357,"twenty":-2.457784,"median":-0.583361,"eighty":0.260287,"marketCap":3332969},{"date":"2024-09-06","current":-0.127907,"twenty":-2.457784,"median":-0.577032,"eighty":0.260287,"marketCap":3191661},{"date":"2024-09-13","current":-0.136062,"twenty":-2.457784,"median":-0.576354,"eighty":0.260287,"marketCap":3395144},{"date":"2024-09-20","current":-0.06645,"twenty":-2.457784,"median":-0.572055,"eighty":0.260287,"marketCap":1658126},{"date":"2024-09-27","current":-0.096959,"twenty":-2.457784,"median":-0.570105,"eighty":0.260287,"marketCap":2419411},{"date":"2024-10-04","current":-0.091033,"twenty":-2.457784,"median":-0.570105,"eighty":0.260287,"marketCap":2271558},{"date":"2024-10-11","current":-0.080691,"twenty":-2.457784,"median":-0.570105,"eighty":0.260287,"marketCap":2013487},{"date":"2024-10-18","current":-0.086509,"twenty":-2.457784,"median":-0.570105,"eighty":0.260287,"marketCap":2158652},{"date":"2024-10-25","current":-0.132995,"twenty":-2.457784,"median":-0.564259,"eighty":0.260287,"marketCap":3318625},{"date":"2024-10-31","current":-0.150717,"twenty":-2.457784,"median":-0.564259,"eighty":0.260287,"marketCap":3760840},{"date":"2024-11-08","current":-0.175098,"twenty":-2.458458,"median":-0.556208,"eighty":0.261026,"marketCap":4153322},{"date":"2024-11-15","current":-0.188079,"twenty":-2.458458,"median":-0.539719,"eighty":0.261026,"marketCap":4461412},{"date":"2024-11-22","current":-0.208213,"twenty":-2.458458,"median":-0.506442,"eighty":0.261026,"marketCap":4939024},{"date":"2024-11-29","current":-0.218593,"twenty":-2.458458,"median":-0.489951,"eighty":0.261026,"marketCap":5185234},{"date":"2024-12-06","current":-0.210499,"twenty":-2.458458,"median":-0.476778,"eighty":0.261026,"marketCap":4993253},{"date":"2024-12-13","current":-0.118749,"twenty":-2.458458,"median":-0.434525,"eighty":0.261026,"marketCap":2816835},{"date":"2024-12-20","current":-0.095547,"twenty":-2.458458,"median":-0.409837,"eighty":0.261026,"marketCap":2266476},{"date":"2024-12-27","current":-0.107781,"twenty":-2.458458,"median":-0.399792,"eighty":0.261026,"marketCap":2556665},{"date":"2025-01-03","current":-0.096391,"twenty":-2.458458,"median":-0.390321,"eighty":0.261026,"marketCap":2286489},{"date":"2025-01-10","current":-0.105039,"twenty":-2.459133,"median":-0.357144,"eighty":0.261765,"marketCap":2491623},{"date":"2025-01-17","current":-0.095125,"twenty":-2.459133,"median":-0.333049,"eighty":0.261765,"marketCap":2256470},{"date":"2025-01-24","current":-0.097235,"twenty":-2.459133,"median":-0.318538,"eighty":0.261765,"marketCap":2306502},{"date":"2025-01-31","current":-0.094071,"twenty":-2.459133,"median":-0.30666,"eighty":0.261765,"marketCap":2231453},{"date":"2025-02-07","current":-0.090907,"twenty":-2.459133,"median":-0.293851,"eighty":0.261765,"marketCap":2156405},{"date":"2025-02-14","current":-0.076775,"twenty":-2.459133,"median":-0.282033,"eighty":0.261765,"marketCap":1821186},{"date":"2025-02-21","current":-0.206104,"twenty":-2.459133,"median":-0.27524,"eighty":0.261765,"marketCap":4973297},{"date":"2025-02-28","current":-0.216984,"twenty":-2.459133,"median":-0.270257,"eighty":0.261765,"marketCap":5235817},{"date":"2025-03-07","current":-0.161982,"twenty":-2.459807,"median":-0.264668,"eighty":0.262505,"marketCap":3908632},{"date":"2025-03-14","current":-0.14385,"twenty":-2.459807,"median":-0.262269,"eighty":0.262505,"marketCap":3471099},{"date":"2025-03-21","current":-0.149284,"twenty":-2.459807,"median":-0.26082,"eighty":0.262505,"marketCap":3602213},{"date":"2025-03-28","current":-0.075551,"twenty":-2.459807,"median":-0.257454,"eighty":0.262505,"marketCap":1823056},{"date":"2025-03-31","current":-0.067694,"twenty":-2.459807,"median":-0.255606,"eighty":0.262505,"marketCap":1633458}],"updateTime":1743581504684}}}